Posted 30 June, 2023
INTENSITY THERAPEUTICS, INC. IPO completed
IPO completed detected for ticker Nasdaq:INTS in a 424B4 filed on 30 June, 2023.
This is our initial public offering.
Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of INTENSITY THERAPEUTICS, INC.
None • None
Intensity Therapeutics, Inc. engages in the operation a biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Westport, CT.Market Cap
$62.9M
View Company Details
$62.9M
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.